Zoë Y G J van Lierop1, Sander Jentjens2, Monique H M E Anten1,3, Roel Wierts2, Connie T Stumpel3,4, Bas Havekes5, Marinus J P G van Kroonenburgh3,2. 1. Department of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands. 2. Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands. 3. Neurofibromatosis Expert Team, Maastricht University Medical Centre, Maastricht, The Netherlands. 4. Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands. 5. Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
Abstract
PURPOSE: To investigate thyroid gland characteristics on 18F-FDG positron emission tomography/computed tomography (PET/CT) imaging in patients with neurofibromatosis type 1 (NF1). SUBJECTS AND METHODS: Thyroid gland characteristics of patients with a clinical diagnosis of NF1 who underwent 18F-FDG PET/CT imaging for the first time to distinguish benign neurofibroma from malignant peripheral nerve sheath tumor (MPNST) at our institution (n = 69) were compared to PET/CT imaging of sarcoidosis (n = 25) and early stage lung cancer (T1N0M0 tumors, n = 15) patients. RESULTS: Two NF1 patients (3%) showed a diffuse 18F-FDG uptake in the thyroid gland, 2 patients (3%) had an irregular uptake, and 7 patients (10%) had a focal uptake. Among the sarcoidosis patients, 1 showed a diffuse uptake (4%) and 1 had an irregular uptake (4%). In the early stage lung cancer group, 1 patient showed a diffuse uptake (7%) and 1 had a focal uptake (7%). NF1 patients had larger mean thyroid volume and mean SUVmax compared to sarcoidosis patients but not compared to early stage lung cancer patients. Four NF1 patients were diagnosed with multinodular goiter, 2 patients were diagnosed with benign chronic lymphocytic thyroiditis, 1 patient had metastasis to the thyroid, and 1 patient had medullary thyroid cancer. CONCLUSION: Even though NF1 patients did not show an increased risk of thyroid incidentaloma on PET/CT compared to previous studies on non-thyroid cancer patients, the incidence shows that awareness of possible thyroid disease is important.
PURPOSE: To investigate thyroid gland characteristics on 18F-FDG positron emission tomography/computed tomography (PET/CT) imaging in patients with neurofibromatosis type 1 (NF1). SUBJECTS AND METHODS: Thyroid gland characteristics of patients with a clinical diagnosis of NF1 who underwent 18F-FDG PET/CT imaging for the first time to distinguish benign neurofibroma from malignant peripheral nerve sheath tumor (MPNST) at our institution (n = 69) were compared to PET/CT imaging of sarcoidosis (n = 25) and early stage lung cancer (T1N0M0 tumors, n = 15) patients. RESULTS: Two NF1 patients (3%) showed a diffuse 18F-FDG uptake in the thyroid gland, 2 patients (3%) had an irregular uptake, and 7 patients (10%) had a focal uptake. Among the sarcoidosis patients, 1 showed a diffuse uptake (4%) and 1 had an irregular uptake (4%). In the early stage lung cancer group, 1 patient showed a diffuse uptake (7%) and 1 had a focal uptake (7%). NF1 patients had larger mean thyroid volume and mean SUVmax compared to sarcoidosis patients but not compared to early stage lung cancer patients. Four NF1 patients were diagnosed with multinodular goiter, 2 patients were diagnosed with benign chronic lymphocytic thyroiditis, 1 patient had metastasis to the thyroid, and 1 patient had medullary thyroid cancer. CONCLUSION: Even though NF1 patients did not show an increased risk of thyroid incidentaloma on PET/CT compared to previous studies on non-thyroid cancer patients, the incidence shows that awareness of possible thyroid disease is important.
Authors: Sun Jin Lee; Semin Chong; Kyung Ho Kang; Joonho Hur; Byung-Woo Hong; Hyun Jung Kim; Soo Jin Kim Journal: AJR Am J Roentgenol Date: 2014-11 Impact factor: 3.959
Authors: B Nygaard; T Nygaard; M Court-Payen; L Ingeman Jensen; P Søe-Jensen; K Gerhard Nielsen; M Fugl; L Hegedüs Journal: Acta Radiol Date: 2002-05 Impact factor: 1.990
Authors: Martin Barrio; Johannes Czernin; Michael W Yeh; Miguel F Palma Diaz; Pawan Gupta; Martin Allen-Auerbach; Christiaan Schiepers; Ken Herrmann Journal: Nucl Med Commun Date: 2016-12 Impact factor: 1.690